ENTLEP 001
Alternative Names: ENTLEP-001Latest Information Update: 11 Sep 2024
At a glance
- Originator Entos Pharmaceuticals
- Class Gene therapies; Obesity therapies
- Mechanism of Action Gene transference; Leptin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Congenital generalised lipodystrophy; Obesity
Most Recent Events
- 30 Aug 2024 Preclinical trials in Congenital generalised lipodystrophy in Canada (Parenteral), prior to August 2024 (Entos Pharmaceuticals pipeline, August 2024)
- 30 Aug 2024 Preclinical trials in Obesity in Canada (Parenteral), prior to August 2024 (Entos Pharmaceuticals pipeline, August 2024)